Robert C. Goeltz II, Chief Financial Officer at Arcus Biosciences, Inc. (RCUS), sold 4,519 shares at $30.66 ($139K) on 2022-12-16, disclosed to the SEC on 2022-12-16.
Open-market sale of $139k RCUS by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.66 | 2,066 | $63K | 45.6% |
| 2 | $30.66 | 2,066 | $63K | 45.6% |
| 3 | $31.23 | 387 | $12K | 8.7% |
| Total | $30.71 avg | 4,519 | $139K | 100% |
| Filing → |
| RCUS | SELL | 2025-12-18 | $557K | — | Filing → |
| RCUS | SELL | 2025-11-26 | $125K | — | Filing → |
| RCUS | SELL | 2025-10-29 | $100K | — | Filing → |